Introduction {#S1}
============

Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis is a systemic small-vessel vasculitis ([@B1]). The major target antigens of ANCA are myeloperoxidase (MPO) and proteinase 3 (PR3). Neutrophils primed by pro-inflammatory cytokines, such as TNF-α, express MPO and PR3 on the cell surface. ANCA bind to the antigens and then activate neutrophils directly and/or through binding to bystander Fcγ receptors. Consequently, the activated neutrophils induce vascular endothelial cell injury resulting in the development of small-vessel vasculitis ([@B2], [@B3]). ANCA, therefore, play a critical role in the pathogenesis of ANCA-associated vasculitis. Although the mechanism of MPO-ANCA production was unknown for a long time, recent studies have suggested the involvement of neutrophil extracellular traps (NETs) in the mechanism ([@B4]--[@B6]).

Neutrophil extracellular traps are firstly reported in 2004 as extracellular web-like DNA studded with antimicrobial proteins, including MPO, which are released from phorbol myristate acetate (PMA)-stimulated neutrophils ([@B7]). The PMA-stimulated neutrophils undergo cell death with the formation of NETs ([@B8]), though not all stimuli induce cell death in NET-forming neutrophil ([@B9]). It has been demonstrated that NET formation can occur with preservation of living neutrophilic functions, including phagocytosis and chemotaxis ([@B10], [@B11]). Currently, NET formation undergoing cell death is called suicidal NETosis, whereas that preserves living neutrophilic functions is called vital NETosis. NETs can trap microorganisms by the extracellular DNA and kill them using the antimicrobial proteins. Thus, NETosis is considered as an important event in innate immunity. However, excessive NETosis can result in vascular endothelial cell injury ([@B12]), thrombosis ([@B13], [@B14]), and impairment of diabetic wound healing ([@B15], [@B16]). In addition, disordered regulation of NETosis has been suggested to be involved in the pathogenesis of autoimmune diseases, including systemic lupus erythematosus (SLE) ([@B17]) and anti-thyroid drug propylthiouracil (PTU)-induced MPO-ANCA-associated vasculitis ([@B5]). In the last two studies, the possibility of extracellular components in persistent NETs recognized as autoantigens by the immune system was discussed.

Suicidal NETosis is induced in response to diverse stimuli, including PMA ([@B7], [@B18]). These stimuli activate the Raf--mitogen-activated protein kinase kinase--extracellular signal-regulated kinase pathway, NADPH oxidase-dependent production of reactive oxygen species, and receptor-interacting protein kinase/mixed lineage kinase domain-like-mediated signals ([@B19], [@B20]). In this pathway, peptidylarginine deiminase 4 (PAD4) yields citrullination of histones, around which DNA coils.

The PAD enzymes convert arginine residues to citrulline in a variety of protein substrates ([@B21]). Among the PAD family, which includes PAD 1--4 and 6, PAD4 is expressed mainly in hematopoietic cells, such as neutrophils ([@B22]). In the process of suicidal NETosis, PAD4-dependent citrullination of histones that yields decondensation of DNA is an essential step to mix DNA and intracytoplasmic proteins. This mixture is subsequently extruded from the ruptured plasma membrane. Accordingly, PAD4 plays a pivotal role in the process of suicidal NETosis ([@B23]).

In the present study, we aimed to determine if a pan-PAD inhibitor, Cl-amidine, could suppress MPO-ANCA production *in vivo*. For this purpose, we attempted to generate novel mouse models of MPO-ANCA-associated vasculitis according to our previous protocol utilized for establishment of a rat model of this disease ([@B5]). The mouse models would be more useful models that require lower doses of reagents than the rat model.

Materials and Methods {#S2}
=====================

Human Neutrophil Isolation {#S2-1}
--------------------------

Human peripheral blood neutrophils were obtained from healthy volunteers by density centrifugation using Polymorphprep (Axis-Shield, Dundee, Scotland) according to the manufacturer's instructions.

NET Induction *In Vitro* {#S2-2}
------------------------

The *in vitro* NET induction was conducted similarly to our earlier study ([@B5]). In brief, human peripheral blood neutrophils were re-suspended in RPMI 1640 medium supplemented with 5% fetal bovine serum and then seeded in wells of 4-well chamber slides (Thermo Fisher Scientific, Yokohama, Japan) (1 × 10^6^/ml). After incubation for 30 min at 37°C, the cells were exposed to 0 or 20 nM PMA (Sigma-Aldrich, St. Louis, MO, USA) with or without 20 μM PTU (Chugai Pharmaceutical, Tokyo, Japan) and incubated for another 2 h at 37°C.

PAD Inhibitor Administration *In Vitro* {#S2-3}
---------------------------------------

Fifteen minutes prior to the PMA/PTU administration, 200 μM Cl-amidine (Calbiochem, San Diego, CA, USA), a pan-PAD inhibitor, was added alternately into the wells. The concentration of Cl-amidine was adopted according to the previous report ([@B24]).

Quantification of NETs *In Vitro* {#S2-4}
---------------------------------

After 2 h of incubation, the medium containing the reagents was removed, and the remaining cells were washed with PBS followed by fixation with 4% paraformaldehyde for 15 min. Thereafter, the specimens were made to react with 5 μg/ml of rabbit anti-human citrullinated histone 3 polyclonal antibody (Abcam, Cambridge, UK) for 60 min at room temperature. After removal of unbound antibody, the specimens were next allowed to react with 1:500 dilution of Alexa Fluor 594-conjugated goat anti-rabbit IgG antibody (Invitrogen, Tokyo, Japan) for 60 min at room temperature. After washing with PBS, the specimens were finally mounted with the 4′, 6-diamidino-2-phenylindole (DAPI)-containing solution (Sigma-Aldrich). NET formation was observed under a fluorescent microscope and was quantified by counting the citrullinated histone 3-positive cells per × 100 power field of view. Data from five random fields of view (×100) were subjected to the quantitative analysis.

Establishment of Mouse Models with MPO-ANCA Production {#S2-5}
------------------------------------------------------

BALB/c, New Zealand White (NZW), C57BL/6N (B6/N), C57BL/6J (B6/J), and DBA mice (14-week-old female) were purchased from Clea Japan (Tokyo, Japan). The mice were given intraperitoneal (i.p.) injection of PMA (50 ng at days 0 and 7) and oral administration of PTU dissolved in 5% glucose water for 4 weeks (*n* = 5/strain). Since preliminary experiments revealed that each mouse ingested at least 2.5 ml of the drug-containing glucose water, the concentration of PTU was set as 1 mg/ml in order to administer exactly 2.5 mg PTU per day. These mice were maintained under specific pathogen-free condition in accordance with the guidelines for the care and use of laboratory animals in Hokkaido University (Permission No. 12-0077).

Laboratory Data {#S2-6}
---------------

Mouse urine was collected during the last 24 h using metabolic cages. Blood samples were obtained at days 14 and 28. Hematuria was assessed by dipsticks (Siemens Healthcare, Tokyo, Japan). Biochemical examinations for blood nitrogen urea (BUN) and creatinine (Cr) were performed at Daiichi Kishimoto Clinical Laboratory (Sapporo, Japan). Serum titer of MPO-ANCA was determined by enzyme-linked immunosorbent assay (ELISA) at A-CLIP Institute (Chiba, Japan).

Histological Evaluation {#S2-7}
-----------------------

The lungs, kidneys, and peritoneal tissues were obtained at day 28 and then fixed in 10% formalin. The pulmonary and renal sections were subjected to hematoxylin and eosin staining. The sections of the peritoneal tissues were subjected to immunohistochemistry for citrullinated histone 3 as described previously ([@B25], [@B26]).

PAD Inhibitor Administration *In Vivo* {#S2-8}
--------------------------------------

BALB/c mice (14-week-old female) were given i.p. injection of PMA (50 ng at days 0 and 7) and oral PTU (2.5 mg/day, aforementioned protocol) for 2 weeks. These mice were divided into two groups. The first group was given daily i.p. injection of PBS (200 μl/day) (*n* = 13). The second group was given daily i.p. injection of Cl-amidine (0.3 mg/200 μl PBS/day) (*n* = 7). The dose of Cl-amidine was adopted according to the previous report ([@B27]). Each mouse was administered at least 10 mg/kg of Cl-amidine per day. Mouse urine was collected during the last 24 h using metabolic cages. Blood and tissue samples were obtained at day 14.

Statistical Analysis {#S2-9}
--------------------

The *in vitro* data were presented as mean ± standard deviation (SD) values obtained from experiments repeated for at least five times. The *in vivo* data were also presented as mean ± SD values. Mann--Whitney *U*-tests were applied for statistical evaluation with StatPlus software. *P*-values of \<0.05 were regarded as statistically significant.

Results {#S3}
=======

Effect of PAD Inhibitor on NET Induction *In Vitro* {#S3-1}
---------------------------------------------------

Human peripheral blood neutrophils were exposed to 0 or 20 nM PMA with or without 20 μM PTU. Fifteen minutes prior to PMA/PTU exposure, the neutrophils were treated with or without 200 μM Cl-amidine. Stimulation without PMA did not induce NETs (data not shown). It has been also determined that 200 μM of Cl-amidine did not affect the viability of neutrophils *in vitro* (Figure S1 in Supplementary Material).

The neutrophils stimulated by 20 nM PMA alone formed extended NETs, whereas neutrophils stimulated by 20 nM PMA plus 20 μM PTU formed non-extended round-shaped NETs (Figure [1](#F1){ref-type="fig"}A). These findings corresponded with our earlier observations ([@B5]) and suggested that PTU yielded abnormal conformation of NETs induced by PMA. Although the morphology of NETs was different, both stimuli (PMA alone and PMA plus PTU) were shown to induce citrullination of histone 3 ([@B5]). Therefore, PAD4 was likely involved in the NET induction by these stimuli. As expected, the pan-PAD inhibitor, Cl-amidine (200 μM) inhibited the NET formation induced by both PMA alone and PMA plus PTU *in vitro* (Figures [1](#F1){ref-type="fig"}A,B). Furthermore, these findings suggest that Cl-amidine can inhibit not only the formation of PMA-induced conventional (extended) NETs but also PTU-mediated unconventional (non-extended round-shaped) NETs.

![**Effect of Cl-amidine on NET induction** *in vitro*. Human peripheral blood neutrophils were seeded in wells of 4-well chamber slides (1 × 10^6^/ml). After incubation for 30 min at 37°C, the cells were exposed to 0 or 20 nM PMA with or without 20 μM PTU. Fifteen minutes prior to PMA/PTU administration, 200 μM Cl-amidine was added alternately into the wells. After 2 h of incubation at 37°C, the medium containing the reagents was removed, and the remaining cells were washed with PBS followed by fixation with 4% paraformaldehyde for 15 min. Thereafter, immunofluorescent staining for citrullinated histone 3 was carried out followed by mounting with the DAPI-containing solution. Representative photos **(A)**. Red, citrullinated histone 3; Blue: DNA (original magnification: ×400). Quantification of NET formation **(B)**. NET formation was quantified by counting the citrullinated histone 3-positive cells per × 100 power field of view. Data from five random fields of view (×100) were subjected to quantitative analysis. \*\**p* \< 0.01 in Mann--Whitney *U*-test.](fimmu-07-00227-g001){#F1}

Establishment of Mouse Models with MPO-ANCA Production {#S3-2}
------------------------------------------------------

In our earlier study, WKY rats were employed to establish an animal model of MPO-ANCA-associated vasculitis ([@B5]). In this study, we attempted to establish novel mouse models of MPO-ANCA-associated vasculitis according to the protocol for the rat model. For this purpose, BALB/c, NZW, B6/N, B6/J, and DBA mice (*n* = 5/strain) were given i.p. injection of PMA (50 ng at days 0 and 7) and oral PTU (2.5 mg/day) for 4 weeks (Figure [2](#F2){ref-type="fig"}A). The serum titers of MPO-ANCA at day 28 were 100.4 ± 12.0 ng/ml in BALB/c, 96.1 ± 12.8 ng/ml in NZW, 41.3 ± 0.90 ng/ml in B6/N, 31.6 ± 5.79 ng/ml in B6/J, and 32.0 ± 4.06 ng/ml in DBA mice (Figure [2](#F2){ref-type="fig"}B). Contrary to the rat model, no vasculitic lesion was observed in the lungs and kidneys of all mouse strains examined. Correspondingly, renal dysfunction was not detected in the urine and blood samples. Based on these findings, we employed BALB/c mice to construct the mouse model with MPO-ANCA production. The serum MPO-ANCA titer at day 14 was 79.0 ± 5.70 ng/ml in the BALB/c model. MPO-ANCA was not detected in the vehicle-injected BALB/c mice.

![**Establishment of mouse models with MPO-ANCA production**. Experimental protocol **(A)**. BALB/c, NZW, B6/N, B6/J, and DBA mice (14-week-old female) were given i.p. injection of PMA (50 ng at days 0 and 7) and oral PTU (2.5 mg/day) for 4 weeks (*n* = 5/strain, p.o.: *Per Os*). Mouse urine was collected during the last 24 h using metabolic cages, and then hematuria was assessed by dipsticks. Blood samples were obtained at days 14 and 28, and then the concentrations of BUN and Cr were determined. The lungs, kidneys, and peritoneal tissues were obtained at day 28. Serum titers of MPO-ANCA determined by ELISA were shown with the results of the urinalysis and concentrations of Cr in the serum **(B)**. The normal limit of serum Cr level is 0.4 mg/dl.](fimmu-07-00227-g002){#F2}

Effect of PAD Inhibitor on Citrullination *In Vivo* {#S3-3}
---------------------------------------------------

BALB/c mice (14-week-old female) were given i.p. injection of PMA (50 ng at days 0 and 7) and oral PTU (2.5 mg/day) for 2 weeks. These mice were divided into two groups. The first group was given daily i.p. injection of PBS (200 μl/day) (*n* = 13) and the other group with daily i.p. injection of Cl-amidine (0.3 mg/200 μl PBS/day) (*n* = 7) (Figure [3](#F3){ref-type="fig"}A). At day 14, the peritoneal tissues were subjected to immunohistochemistry for citrullinated histone 3 for the evaluation of NET formation *in vivo*. As a result, the rate of citrullinated histone 3-positive cells in polymorphonuclear cells was significantly reduced in the Cl-amidine-treated mice in comparison with the vehicle-injected control mice (38% reduction) (Figure [3](#F3){ref-type="fig"}B).

![**Effect of Cl-amidine on citrullination and MPO-ANCA production *in vivo***. Experimental protocol **(A)**. BALB/c mice (14-week-old female) were given i.p. injection of PMA (50 ng at days 0 and 7) and oral PTU (2.5 mg/day) for 2 weeks (p.o.: *Per Os*). These mice were divided into two groups. The first group of mice was given daily i.p. injection of PBS (200 μl/day) (*n* = 13). The other group was given daily i.p. injection of Cl-amidine (0.3 mg/200 μl PBS/day) (*n* = 7). Mouse urine was collected during the last 24 h using metabolic cages. Blood and tissue samples were obtained at day 14. NET formation in peritoneal tissues **(B)**. The formalin-fixed paraffin-embedded sections of peritoneal tissues were subjected to immunohistochemistry for citrullinated histone 3. Representative photos among five random fields of view (×100) were shown. NET induction was quantified by calculating the rate of citrullinated histone 3-positive cells in polymorphonuclear cells in the five random fields of view. \**p* \< 0.05 in Mann--Whitney *U*-test. Serum titers of MPO-ANCA determined by ELISA **(C)**. \*\**p* \< 0.01 in Mann--Whitney *U*-test.](fimmu-07-00227-g003){#F3}

Effect of PAD Inhibitor on MPO-ANCA Production *In Vivo* {#S3-4}
--------------------------------------------------------

The serum titers of MPO-ANCA in the Cl-amidine-treated mice (32.3 ± 31.0 ng/ml) were significantly lower than the vehicle-injected control mice (132.1 ± 41.6 ng/ml) (Figure [3](#F3){ref-type="fig"}C). The collective findings clearly indicate that NET formation is inhibited by the pan-PAD inhibitor, Cl-amidine, both *in vitro* and *in vivo*, and that MPO-ANCA production is suppressed by Cl-amidine *in vivo*.

Discussion {#S4}
==========

The PMA-stimulated neutrophils extrude decondensated DNA, which forms extracellular web-like structures decorated with bactericidal proteins ([@B7]). Since this substance, called NETs, can bind and kill bacteria, NET formation is regarded as an important event in innate immunity. Chronic granulomatous disease (CGD) patients who cannot generate NETs are susceptible to diverse bacteria and fungi indeed, and it was shown that restoration of NET formation in CGD resulted in resistance to such infections ([@B28]). Currently, it is considered that NET appears to be a form of innate response that binds microorganisms, prevents them from spreading, and ensures a high local concentration of antimicrobial agents derived from neutrophils ([@B29]).

The PMA-stimulated neutrophils undergo cell death with NET formation ([@B8]). Since the characteristics of cell death resembled neither typical necrosis nor apoptosis, Steinberg et al. coined NETosis for the neutrophil death with NET formation ([@B30]). However, Clark et al. have demonstrated that neutrophils do not necessarily undergo cell death after NET formation ([@B31]). It has been shown that NET formation can occur with preservation of neutrophilic functions, including phagocytosis and chemotaxis ([@B10], [@B11]). This phenomenon termed vital NETosis ([@B9]). On the contrary, aforementioned dying NETosis has been called suicidal NETosis.

Although NETs play an essential role in the innate immunity, some harmful aspects of NETs have been demonstrated ([@B32], [@B33]). They not only have direct cytotoxic and thrombotic effects on vascular endothelium ([@B12]--[@B14]), but NETs are also associated with pathogenic autoantibody production ([@B5], [@B17]). For example, impairment of NET degradation potential (low activity of DNase I) in the serum is present in 30--40% of patients with SLE and is suggested to lead the production of anti-DNA antibodies, which are related to disease severity ([@B17]). In another case, morphologically abnormal and DNase I-resistant NETs are generated by the anti-thyroid drug, PTU, and then MPO in the NETs seems to be recognized by the immune system resulting in the production of MPO-ANCA in rats administered with PTU ([@B5]). It has been shown that a part of PTU is metabolized by MPO. Simultaneously, conformational alteration of MPO could be induced by PTU ([@B34]), which could result in the tolerance break to MPO.

In the present study, we established mouse models with MPO-ANCA production. We treated five strains of mouse with PMA and PTU corresponding to the previously established protocol for the rat model of MPO-ANCA-associated vasculitis. Interestingly, there was a strain-dependency in the response to produce MPO-ANCA in mouse. Although the precise mechanism of the strain-dependency has to be determined in future studies, the Th2 phenotype of BALB/c ([@B35]) and autoimmune-prone genetic background of NZW ([@B36]) may be associated with the susceptibility to produce autoantibodies. In addition, no vasculitic lesion was observed in the mouse models with MPO-ANCA production, whereas WKY rats with MPO-ANCA developed pulmonary capillaritis and glomerulonephritis ([@B5]). Species-dependency may be present in the development of PMA plus PTU-induced MPO-ANCA-associated vasculitis. Nonetheless, we employed BALB/c mice to construct *in vivo* models of MPO-ANCA production.

Neeli et al. first demonstrated that PAD4-dependent histone deimination occurred in activated neutrophils under inflammatory conditions ([@B37]). Since PAD4-deficient neutrophils did not generate NETs in response to PMA, PAD4 plays a pivotal role in the NET formation ([@B23]). Correspondingly, inhibition of PAD4 using the pan-PAD inhibitor, Cl-amidine, prevented citrullination of histone 3 and significantly reduced NET release from HL60 cells, which were differentiated into mature neutrophils, in response to Ca^2+^ ionophore or *Shigella flexneri* exposure ([@B24]). In addition, Cl-amidine has been shown to suppress NET formation in lupus-prone mice ([@B27]). It has been shown that Cl-amidine can modify the cysteine of PAD and then inactivate it irreversibly ([@B38]). Based on these findings, we conducted *in vitro* and *in vivo* experiments to inhibit citrullination/NET formation using Cl-amidine as a pan-PAD inhibitor. The present study reproduced and extended the results of previous reports that investigated Cl-amidine both *in vitro* and *in vivo* and demonstrated that MPO-ANCA production was suppressed by Cl-amidine *in vivo*. These findings suggest that excessive formation of NETs may be implicated in MPO-ANCA production *in vivo*. In order to demonstrate the direct implication of PAD4-dependent NET formation in MPO-ANCA production, further studies using PAD4-deficient mice should be designed.

One limitation of this study is the lack of quantification of released NETs, which can be usually detected as MPO-DNA complexes in the serum. However, it has been shown that the PMA plus PTU-induced NETs hardly converted into soluble form ([@B5]). Thus, there is no better methodology to evaluate NETs in the murine model than the immunohistochemistry for citrullinated histone 3.

No vasculitic phenotype was observed in the PMA plus PTU-induced mouse models with MPO-ANCA production. Therefore, we could not examine the effect of PAD inhibitors on MPO-ANCA-associated vasculitis in this model, which is another limitation of this study. It should be determined whether increased doses of PMA/PTU and/or longer duration could induce vasculitis in the mouse models in future studies.

It has been shown that MPO-ANCA is the major pathogenic factor in MPO-ANCA-associated vasculitis ([@B2], [@B3]). Thus, it is expected that PAD inhibitors, which can suppress the production of the pathogenic autoantibody, would be applied for the treatment of patients with MPO-ANCA-associated vasculitis. Preceding studies have demonstrated the protective effects of PAD inhibitors on the models of SLE ([@B27]) and other NET-related diseases, including multiple sclerosis ([@B39]), collagen-induced arthritis ([@B40]), and inflammatory bowel disease ([@B41]). Although further studies are needed to clarify their safety and effectiveness, PAD inhibitors are potential candidates as novel therapeutic agents for various NET-related diseases, including MPO-ANCA-associated vasculitis.
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